Description
COMPOSITION:
Each film-coated Lucicapma tablet contains: Capmatinib HCL (anhydrous) 235.40 mg equivalent to Capmatinib 200mg
INDICATION:
LuciCapma is for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC).
DOSAGE AND USE:
Recommended dosage: 400 mg orally twice daily with or without food.
Tablets should be swallowed whole & not chewed or crushed.
STORAGE:
in a dry place and store at 20°C to 25°C
MANUFACTURED AND MARKETED BY:
LUCIUS PHARMACEUTICALS(LAO) CO., LTD
No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos
WARNING:
Keep medicine out of the reach of Children. Do not administered LuciCapma in Pregnancy and Lactation patient treatment.
Reviews
There are no reviews yet.